Discussion
The U.S. Food and Drug Administration (FDA) has given Gain Therapeutics a green light to launch a clinical trial — to run across three continents — testing GT-02287, an oral therapy designed to prevent the formation of toxic protein clumps in Parkinson’s disease. The agency clearance follows positive early…
